Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINATION BETA-LACTAM AND BETA-LACTAMASE-INHIBITOR THERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
Autore:
DUDLEY MN;
Indirizzi:
UNIV RHODE ISL,ROGER WILLIAMS MED CTR,ANTIINFECT PHARMACOL RES UNIT,825 CHALKSTONE AVE PROVIDENCE RI 02908
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 6, volume: 52, anno: 1995, supplemento:, 2
pagine: 23 - 28
SICI:
1079-2082(1995)52:6<23:CBABT->2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESCHERICHIA-COLI; CLAVULANIC ACID; FAMILY ENTEROBACTERIACEAE; PIPERACILLIN-TAZOBACTAM; AMPICILLIN-SULBACTAM; RESISTANCE; TEM-1; MODEL;
Keywords:
ANTIBIOTICS; DOSAGE SCHEDULES; ENZYME INHIBITORS; PHARMACODYNAMICS; PHARMACOKINETICS; RESISTANCE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
M.N. Dudley, "COMBINATION BETA-LACTAM AND BETA-LACTAMASE-INHIBITOR THERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS", American journal of health-system pharmacy, 52(6), 1995, pp. 23-28

Abstract

Pharmacokinetic and pharmacodynamic considerations in in vitro susceptibility testing are described, and the integration of pharmacokineticand pharmacodynamic concepts in dosage-regimen design is explored. Both the amount of beta-lactamase produced per unit of time and the amount of beta-lactamase inhibitor supplied greatly influence susceptibility to beta-lactam antibiotics. The goal should be to supply enough beta-lactamase to render the bacteria functionally beta-lactamase negative. In susceptibility testing, the amount of inhibitor may be more important than the ratio between the beta-lactam antibiotic and the inhibitor. Irreversible inactivation of beta-lactamases by inhibitors allowsfor a period of killing of bacteria by beta-lactams, even when concentrations of the inhibitor fall to concentrations below those tested invitro. The integration of pharmacokinetic and pharmacodynamic concepts allows for comparisons between in vitro and in vivo drug exposure: With some antibiotic-inhibitor combinations, it may be possible to extend the dosage interval if an adequate amount of inhibitor is provided over the course of therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 05:55:03